|
Session 92
Poster Abstracts
Clinical Trials of Entry Inhibitors
Monday, 1 - 4 pm
Poster Hall |
| 509 |
A Review of the Markers of Immune Function during the Maraviroc Phase I and IIa Studies
A Ayoub, E Van der Ryst, K Turner, and Mary McHale*
Pfizer Global R&D, Sandwich, UK |
| 510 |
A Randomized, Double-blind, Placebo-controlled Study of Adding Vicriviroc to ART in Patients with Hepatitis C Co-infection
Gerd Fätkenheuer*1, C Hoffmann2, J Slim3, R Nougarede4, A Keung5, J Li5, M Treitel5, A Sansone5, and D Schürmann6
1Univ of Cologne, Germany; 2ifi Inst, Hamburg, Germany; 3St Michael's Hosp, Newark, NJ, US; 4CentreCap, Montpellier, France; 5Schering Plough, Kenilworth, NJ, US; and 6Charite Univ Hosp, Berlin, Germany |
511
 |
CXCR4 Antagonism: Proof of Activity with AMD11070
Graeme Moyle*1, E DeJesus2, M Boffito1, R Wong3, E Coakley4, C Gibney3, K Badel3, G Calandra3, G Bridger3, and S Becker3
1Chelsea and Westminster Hosp, London, UK; 2Orlando Immunology Ctr, FL, US; 3AnorMED Inc, Langley, Canada; and 4Monogram Biosci, South San Francisco, CA, US |
| 512 |
Proof of Concept of Antiretroviral Activity of AMD11070 (an Orally Administered CXCR4 Entry Inhibitor): Results of the First Dosing Cohort A Studied in ACTG Protocol A5210
Michael Saag*1, S Rosenkranz2, S Becker3, K Klingman4, B Kallungal5, A Zadzilka6, E Coakley7, E Acosta1, G Calandra3, V Johnson1, and NIAID AIDS Clinical Trials Group, Bethesda, MD USA
1Univ of Alabama at Birmingham, US; 2Harvard Univ, Statistical and Data Analysis Ctr, Boston, MA, US; 3AnorMED Inc, Langley, Canada; 4NIAID, NIH, Bethesda, MD, US; 5ACTG Operations Office, Silver Spring, MD, US; 6Frontier Sci & Tech Res Fndn, Amherst, NY, US; and 7Monogram Biosci, South San Francisco, CA, US |
|
